4BASEBIO UK SOCIETAS (LSE:4BB) — Market Cap & Net Worth
Market Cap & Net Worth: 4BASEBIO UK SOCIETAS (4BB)
4BASEBIO UK SOCIETAS (LSE:4BB) has a market capitalization of $951.45K (GBX7.82 Billion) as of May 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30242 globally and #809 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 4BASEBIO UK SOCIETAS's stock price GBX505.00 by its total outstanding shares 15484875 (15.48 Million). Analyse 4BB operating cash flow to see how efficiently the company converts income to cash.
4BASEBIO UK SOCIETAS Market Cap History: 2021 to 2026
4BASEBIO UK SOCIETAS's market capitalization history from 2021 to 2026. Data shows growth from $1.16 Million to $951.45K (8.05% CAGR).
Index Memberships
4BASEBIO UK SOCIETAS is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$928.14 Million | 0.10% | #161 of 722 |
Weight: 4BASEBIO UK SOCIETAS's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
4BASEBIO UK SOCIETAS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 4BASEBIO UK SOCIETAS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.44x
4BASEBIO UK SOCIETAS's market cap is 2.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.16 Million | $338.00K | -$3.23 Million | 3.43x | N/A |
| 2022 | $1.34 Million | $268.00K | -$5.15 Million | 4.99x | N/A |
| 2023 | $1.28 Million | $506.00K | -$7.67 Million | 2.53x | N/A |
| 2024 | $2.28 Million | $933.00K | -$12.33 Million | 2.44x | N/A |
Competitor Companies of 4BB by Market Capitalization
Companies near 4BASEBIO UK SOCIETAS in the global market cap rankings as of May 5, 2026.
Key companies related to 4BASEBIO UK SOCIETAS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
4BASEBIO UK SOCIETAS Historical Marketcap From 2021 to 2026
Between 2021 and today, 4BASEBIO UK SOCIETAS's market cap moved from $1.16 Million to $ 951.45K, with a yearly change of 8.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX951.45K | -17.89% |
| 2025 | GBX1.16 Million | -49.17% |
| 2024 | GBX2.28 Million | +77.94% |
| 2023 | GBX1.28 Million | -4.23% |
| 2022 | GBX1.34 Million | +15.45% |
| 2021 | GBX1.16 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of 4BASEBIO UK SOCIETAS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $951.45K USD |
| MoneyControl | $951.45K USD |
| MarketWatch | $951.45K USD |
| marketcap.company | $951.45K USD |
| Reuters | $951.45K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 4BASEBIO UK SOCIETAS
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more